Last week, The Lancet presented a peer-reviewed paper [1] on hydroxychloroquine, indicating in an observational study that the risk of cardiac arrhythmias outweighed its beneficial use. In addition to the scientific interest, the article was seized upon by those political talking heads that have been concerned with President Trump’s advocacy of what was felt to be an untested and ineffective treatment.

Perhaps you've noticed: Hospitals are asking you to come back for your routine care. Amongst the surge in caring for COVID-19 patients, elective care, especially remunerative procedural care, was pushed to the sidelines. One source suggests that overall cancer care has decreased by 37% during the pandemic.

Infectious disease models can also describe riots. The spread of coronavirus and violent protests share many features in common, shedding at least some light on the coming summer of discontent.

EIDD-2801, one of the most promising coronavirus antiviral drugs, just lept ahead of the pack. Merck has partnered with Ridgeback Biologics to develop the drug. It has a lot going for it. Here's why.

People are hungry for information about the coronavirus. But are some media outlets exploiting the situation to promote themselves?

Royce Chen, M.D., an ophthalmologic surgeon at NY-Presbyterian Hospital, was looking at far more than eyes once the COVID-19 pandemic hit New York. He and other physicians were redeployed to the ICU to help care for the new influx of patients. His article addresses an interesting question - which specialties were hardest hit? And how did physicians in the New York area feel about the PPE provided for them? (Hint: not so good.)

The satisfaction of handwork; as we reconsider our economy, is there still a place for small, rather than large; a musing on addiction's social component, and can the outliers of the herd teach us about how to return to social mingling.

Currently, COVID-19 vaccines are all the rage. Expectations are not only high, they are too high. ACSH friend, and former trustee, Dr. Paul Offit gives us a much-needed reality check. A vaccine, especially a very effective one, is unlikely to be in the cards anytime soon. Although it is always better to prevent an infection than treat one, antiviral drugs are likely to be the tools to control coronavirus well before a vaccine appears.Here's how Dr. Offit sees this playing out.

The COVID-19 lockdown is responsible for both the loss of economic activity and human lives. Two independent groups of researchers concluded that the lockdown may be costing more lives than it saves.

Throughout the coronavirus crisis, the co-authors of this article have often held opposite viewpoints on many aspects of the issue. Despite coming from different disciplines with competing perspectives, they join forces to address puzzling questions about coronavirus mortality statistics.